VORLÄUFIGE ENDERGEBNIS DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
Finanz und Wirtschaft EQS-Ad-hoc: Cosmo Pharmaceuticals N.V. / Schlagwort(e): Firmenübernahme
COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN DAS VORLÄUFIGE
ENDERGEBNIS DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM
BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
03.12.2021 / 06:00 GMT/BST
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
------------------------------------------------------------
Ad-hoc-Mitteilung gemäss Art. 53 LR
Dublin, Irland und Lainate, Italien - 3. Dezember 2021 - Cosmo Pharmaceuticals
N.V. (SIX: COPN) ("Cosmo") und Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") haben
heute die vorläufigen Endergebnisse des öffentlichen Umtauschangebots von Cosmo
gemäss Artikel 125 ff. des Bundesgesetzes über die Finanzmarktinfrastruktur und
das Marktverhalten im Effekten- und Derivatehandel vom 19. Juni 2015 für alle
im Publikum befindlichen Aktien der Cassiopea ("Angebot") bekannt gegeben.
Nach Ablauf der zusätzlichen Annahmefrist am 2. Dezember 2021, 16:00 Uhr (MEZ),
zeigen die vorläufigen Endergebnisse, dass Cosmo im Rahmen des Angebots
insgesamt 5,365,250 Cassiopea Aktien angeboten worden sind, was ca. 93.4% der
Cassiopea Aktien auf die sich das Angebot bezieht, entspricht, was zusammen mit
den bereits von Cosmo gehaltenen Cassiopea Aktien ca. 96.5% der derzeit
ausgegebenen Cassiopea Aktien entspricht.
Die definitive Mitteilung der endgültigen Ergebnisse wird voraussichtlich am 7.
Dezember 2021 veröffentlicht werden.
Die Abwicklung des Angebots wird voraussichtlich am 17. Dezember 2021 erfolgen.
Die Auszahlung der Barabfindung für die Bruchteilsaktien wird voraussichtlich
am 23. Dezember 2021 erfolgen.
Das Angebot unterliegt den im Angebotsprospekt vom 4. Oktober 2021 dargelegten
Angebotsbeschränkungen.
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and
commercialising products to treat selected gastrointestinal disorders and
improve endoscopy quality measures through aiding the detection of colonic
lesions. Cosmo has also developed medical devices for endoscopy and has a
partnership with Medtronic for the global distribution of GI Genius(TM) its
artificial intelligence device that uses artificial intelligence to help detect
potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill
Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the
EU and other countries. For additional information on Cosmo and its products
please visit the Company's website: www.cosmopharma.com
About Cassiopea
Cassiopea is a specialty pharmaceutical company developing and preparing to
commercialize prescription drugs with novel mechanisms of action (MOA) to
address long-standing and essential dermatological conditions, particularly
acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing
in innovation that is driving scientific advancement in areas that have been
largely ignored for decades. The portfolio comprises four unencumbered clinical
candidates, for which Cassiopea owns the worldwide rights. The Company's
strategy is to leverage this expertise to optimize the commercial potential for
its products directly or with partners. For further information on Cassiopea,
please visit www.cassiopea.com.
Contact
Niall Donnelly, CFO & Head of Investor Diana Harbort, CEO & Head of Investor
Relations Relations
Cosmo Pharmaceuticals N.V. Cassiopea S.p.A.
Tel: +353 1 817 03 70 Tel: +39 02 868 911 24,
ndonnelly@cosmopharma.com dharbort@cassiopea.com
Disclaimer
This communication (the "Communication") has been prepared by Cosmo
Pharmaceuticals N.V. ('Cosmo" and together with its subsidiaries, "we", "us" or
the "Group") solely for informational purposes and has not been independently
verified and no representation or warranty, express or implied, is made or
given by or on behalf of any of the Group. Cosmo reserves the right to amend or
replace the Communication at any time, and undertakes no obligation to provide
the recipients with access to any additional information. Cosmo shall not be
obligated to update or correct the information set forth in the Communication
or to provide any additional information. Nothing in this Presentation is, or
should be relied upon as, a promise or representation as to the future.
Certain statements in this Communication are forward-looking statements. By
their nature, forward-looking statements involve a number of risks,
uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could adversely affect
the outcome and financial consequences of the plans and events described
herein. Actual results may differ from those set forth in the forward looking
statements as a result of various factors (including, but not limited to,
future global economic conditions, changed market conditions, intense
competition in the markets in which the Group operates, costs of compliance
with applicable laws, regulations and standards, diverse political, legal,
economic and other conditions affecting the Group's markets, and other factors
beyond the control of the Group). Neither Cosmo nor any of its respective
directors, officers, employees, advisors, or any other person is under any
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. You should not place
undue reliance on forward-looking statements, which speak of the date of this
Communication. Statements contained in this Communication regarding past
trends or events should not be taken as a representation that such trends or
events will continue in the future.
This Communication does not constitute or form part of, and should not be
construed as, an offer or invitation or inducement to subscribe for, underwrite
or otherwise acquire, any securities of Cosmo, nor should it or any part of it
form the basis of, or be relied on in connection with, any contract to purchase
or subscribe for any securities of the Group, nor shall it or any part of it
form the basis of, or be relied on in connection with, any contract or
commitment whatsoever. This Communication constitutes neither an offer to sell
nor a solicitation to buy securities of Cosmo and it does not constitute a
prospectus or similar notice within the meaning of articles 35 et seqq. or 69
of the Swiss Financial Services Act or a prospectus pursuant to the laws of any
other jurisdiction. This Communication may be considered to be marketing
material. The offer [and listing] will be made solely by means of, and on the
basis of, a prospectus which is to be published. An investment decision
regarding the publicly offered securities of Cosmo should only be made on the
basis of the prospectus. The prospectus is expected to be published on or
around 4 October 2021 and will be available free of charge at
https://www.cosmopharma.com/investors.
United States of America
The securities described in this Communication have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "U.S.
Securities Act"), or under any law of any state of the United States of
America, and may not be offered, sold, resold, or delivered, directly or
indirectly, in or into the U.S., except pursuant to an exemption from the
registration requirements of the U.S. Securities Act and applicable state
securities laws. Neither this document nor the exchange offer described herein
constitutes an offer to sell or the solicitation of an offer to buy any
securities in the U.S. or in any other jurisdiction in which such an offer or
solicitation would be unlawful. Cosmo Pharmaceuticals N.V. will not register or
make a public offer of its securities, or otherwise conduct any public tender
offer, in the U.S. In the U.S., this document is being provided to "qualified
institutional buyers" (as defined in Rule 144A under the U.S. Securities Act)
only on a confidential basis. Neither the United States Securities and Exchange
Commission nor any state securities commission in the United States has
approved or disapproved the Offering of the shares or passed upon the adequacy
or accuracy of the Prospectus. Any representation to the contrary is a criminal
offence in the United States. PROSPECTIVE PURCHASERS ARE HEREBY NOTIFIED THAT
SELLERS OF COSMO SHARES MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF
SECTION 5 OF THE US SECURITIES ACT PROVIDED BY RULE 144A.
By tendering securities of Cassiopea S.p.A. into this offer, you will be deemed
to represent that you (x) (a) are not a U.S. person, (b) are not acting for the
account or benefit of any U.S. person, and (c) are not in or delivering the
acceptance from, the United States or (y) you are a "qualified institutional
buyer" as that term is used in Rule 144A under the U.S. Securities Act.
United Kingdom
This Communication is directed only at persons in the U.K. who (i) have
professional experience in matters relating to investments falling within
article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the Order), (ii) are persons falling within article
49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.")
of the Order or (iii) to whom it may otherwise lawfully be communicated (all
such persons together being referred to as Relevant Persons). This
communication must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this communication
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons.
Australia, Canada, Japan
This Communication is not addressed to shareholders of Cassiopea S.p.A. whose
place of residence, seat or habitual abode is in Australia, Canada or Japan,
and such shareholders may not accept the offer.
European Economic Area
The offer set out in this Communication (the Offer) is only being made within
the European Economic Area (EEA) pursuant to an exemption under Regulation (EU)
2017/1129 (as amended and together with any applicable adopting or amending
measures in any relevant member state (as defined below), the Prospectus
Regulation), as implemented in each member state of the EEA (each a relevant
member state), from the requirement to publish a prospectus that has been
approved by the competent authority in that relevant member state and published
in accordance with the Prospectus Regulation as implemented in that relevant
member state or, where appropriate, approved in another relevant member state
and notified to the competent authority in that relevant member state, all in
accordance with the Prospectus Regulation. Accordingly, in the EEA, the Offer
and documents or other materials in relation to the Offer and the shares in
Cosmo Pharmaceuticals N.V. (the Offeror Shares) are only addressed to, and are
only directed at, (i) qualified investors (qualified investors) in the relevant
member state within the meaning of Article 2(1)(e) of the Prospectus
Regulation, as adopted in the relevant member state, and (ii) persons who hold,
and will tender, the equivalent of at least EUR 100,000 worth of shares in
Cassiopea S.p.A. (the Target Shares) in exchange for the receipt of Offeror
Shares (collectively, permitted participants). This offer prospectus and the
documents and other materials in relation to the Offer may not be acted or
relied upon by persons in the EEA who are not permitted participants, and each
Target shareholder seeking to participate in the Offer that is resident in the
EEA will be deemed to have represented and agreed that it is a qualified
investor or that it is tendering the equivalent of EUR 100,000 worth of Target
Shares in exchange of Offeror Shares.
Italy
The offer set out in this Communication (the Offer) does not constitute a
public offer nor a tender or exchange offer nor an advertisement of securities
to the public in the Republic of Italy. Neither the Offer nor the COPN Shares
have been registered with or cleared by the Commissione Nazionale per la
Società e la Borsa ("CONSOB") (the Italian securities exchange commission),
pursuant to Italian securities legislation. Neither the CONSOB nor any other
Italian public authority has examined, approved, cleared or registered this
Prospectus or will examine, approve, clear or register this Offer. Accordingly,
Italian residents cannot participate in the Offer nor may copies of this
Communication or of any other document relating to the Offer be distributed or
published in the Republic of Italy, either on primary and on secondary market.
This Communication has not been prepared in accordance with the prospectus
requirements nor the tender offer requirements provided for, or otherwise
applicable in, Italy. Cosmo Pharmaceutical N.V. will not accept, directly or
indirectly, any order relating to the Offer made in, or coming from, the
Republic of Italy; any such order will be deemed null and void.
General
Cosmo Pharmaceuticals N.V.'s public tender and exchange offer for all publicly
held shares of Cassiopea S.p.A. (the Offer) is not being made, directly or
indirectly, in any country or jurisdiction in which such offer would be
unlawful or otherwise violate any applicable law or regulation or which would
require Cosmo Pharmaceuticals N.V. to make any amendment to the terms or
conditions of the Offer, to make any additional application to, or to take any
additional action with respect to, any governmental, regulatory or legal
authority. It is not intended to extend the Offer to any such country or
jurisdiction. Documents relating to the Offer may not be distributed in, or
sent to, any such country or jurisdiction. Such documents may not be used for
the purpose of soliciting purchases of Cassiopea S.p.A. securities by any
person or entity resident or incorporated in such country or jurisdiction.
This Communication is not for distribution in the United States, Canada,
Australia, Japan or Italy. This communication does not constitute an offer to
sell, or the solicitation of an offer to buy, securities in any jurisdiction in
which is unlawful to do so.
------------------------------------------------------------
Ende der Ad-hoc-Mitteilung
------------------------------------------------------------
Sprache: Deutsch
Unternehmen: Cosmo Pharmaceuticals N.V.
Riverside 2, Sir John Rogerson's
Dublin 2 Dublin
Irland
Telefon: + 353 1 817 0370
E-Mail: info@cosmopharma.com
Internet: https://www.cosmopharma.com/
ISIN: NL0011832936
Börsen: SIX Swiss Exchange
EQS News ID: 1253980
Ende der Mitteilung EQS News-Service
------------------------------------------------------------
1253980 03.12.2021 GMT/BST